Home » Tesaro’s Niraparib Soars in Phase 3 Study
Tesaro’s Niraparib Soars in Phase 3 Study
Tesaro’s niraparib scored in a Phase 3 trial evaluating the treatment in patients suffering from ovarian cancer, meeting its primary endpoint of progression-free survival.
In both cohorts of the study, the candidate significantly extended progression-free survival compared to the control.
Currently, there is no FDA-approved drug for maintenance treatment of patients with recurrent ovarian cancer following a reaction to platinum-based treatments, according to the company.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May